Live Attenuated Vaccines Market Research Report Information, By Type (Bacterial, Viral), By Vaccine Development (Tissue Culture, Embryonated Eggs, Live Animals) and End Users (Hospitals, Clinics, Diagnostic Centers, Research Institute, Others) - Forecast till 2032

Global Live Attenuated Vaccines Market Overview

Live Attenuated Vaccines Market Size was valued at USD 25.30 Billion in 2023. The Global Live Attenuated Vaccines industry is projected to grow from USD 28.93 Billion in 2024 to USD 70.42 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 11.00% during the forecast period (2024 - 2032).

Vaccines created by reducing the virulence of pathogens are known as Live Attenuated Vaccines (LAV). These pathogens are weakened under laboratory conditions. The vaccine triggers a potent immune response against infectious diseases. They initiate memory cell production in order to respond to the pathogen that previously invaded the body. Increasing awareness about vaccination, growing government funding for vaccination programs and increasing prevalence of infectious diseases drive the growth of live attenuated vaccines market. Improving healthcare infrastructure, increasing demand for LAV, and emphasis on prevention of diseases also drives this market.

In June 2023, BoomerangFX, a provider of web-based SaaS (Software as a Service) that caters to non-insured patients with private-pay healthcare services in dermatology, cosmetic surgery, medical spa, cosmetic dentistry, vision care, and women's health, announced an alliance with DrFirst who is a pioneer in healthcare technology; this partnership will enable them to offer their customers a unified medication management platform aimed at maximizing clinical workflows and patient engagement. The research indicates that aesthetic medicine has had an explosion in consumer adoption and is showing its ability to be more immune to recessions over time. Enabling surgeons of cosmetics along with physicians from different disciplines is part of the reality when it comes to increasing demand for various facial and body enhancement procedures using minimally invasive techniques. 

Hamilton Beach Brands Inc., which is Hamilton Beach Brands Holding Company’s wholly-owned subsidiary (NYSE: HBB) and HealthBeacon plc (Euronext: HBCN: ID), a leading developer of smart tools for managing injectable medications at home, announced the availability of Hamilton Beach Health’s Smart Sharps Bin powered by HealthBeacon in the US through new direct-to-consumer website as well as Amazon. This innovative digital health technology could revolutionize how care is delivered to patients on home injection therapies for various chronic illnesses such as diabetes mellitus, rheumatoid arthritis, multiple sclerosis, asthma, obesity, or migraine.

Berry Global has unveiled an innovative child-resistant closure integrated with digital technology that enhances drug adherence. According to the company’s release statement announcing this new product- Berry Digi-Cap Digital Closure –it will find applicability within clinical trials, drug development activities, and academic settings, among others. Data obtained from monitoring patient behavior can improve medication adherence while providing insights into the efficacy of these treatments compared to those set out by doctors. The incorporation of a microprocessor into the closing mechanism allows for recording all cases when there was an opening by patients, as well as keeping in memory the history of its use. The system also monitors and records temperature storage levels continuously, which is useful for research and development purposes.

Study objectives

The main objective of this research is to provide information about live attenuated vaccines market, types of vaccine, vaccine development, and its end users.

• To provide a detailed analysis of the market structure along with the forecast for the next seven years of the various segments and sub-segments of the live attenuated vaccines market.


• To provide insights about factors affecting the market growth.


• To analyze the live attenuated vaccines market based on various factors- price analysis, supply chain analysis, porters five force analysis etc.


• To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- Americas, Europe, Asia Pacific and the Middle East & Africa.


• To provide country level analysis of the market with respect to the current market size and future perspective.


• To provide country level analysis of the market for segments by type, vaccine development, by end users and its sub-segments.


• To provide an overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market.


• To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the live attenuated vaccines market.

Key Players in the Live Attenuated Vaccines Market

• GlaxoSmithKline, plc. (U.K.)


• Merck & Co. (U.S.)


• Pfizer, Inc. (U.S.)


• Astellas Pharma Inc. (Japan)


• Johnson & Johnson (U.S.)


• CSL Limited (Australia)


• Emergent BioSolutions, Inc. (U.S.)


• MedImmune, LLC (U.S.)


• Sanofi (France)


• Serum Institute of India Pvt. Ltd. (India)

Live Attenuated Vaccines Market Segmentation

Live attenuated vaccines market is segmented on the basis of type, which includes bacterial and viral vaccines. Bacterial vaccines includes BCG vaccine, and viral vaccine include oral polio vaccine (OPV), measles, rotavirus, and yellow fewer & other viral vaccines. 

On the basis of vaccine development, the live attenuated vaccines market is segmented into tissue culture, embryonated eggs, live animals, and on the basis of end users, it is sub-segmented into hospitals, clinics, diagnostic centers, research institute & others.

Intended Audience

• Contract Research Organizations (CROs)


• Vaccine Manufacturers


• Vaccine Suppliers


• Government Agencies


• Research and Development (R&D) Companies


• Academic Medical Institutes and Universities

Global Live Attenuated Vaccines Market Regional Analysis

Globally, live attenuated vaccines market consists of four regions America, Europe, Asia Pacific and the Middle East & Africa.  North America is the largest market in the world. Initiatives taken by the government for vaccination against diseases like influenza, as well as excellent management of public awareness programs are boosting the growth of this market in North America. 

Europe is the second largest market owing to availability of funds for R&D activities and growing emphasis on R&D. Asia Pacific shows the fastest growth in this market due to an increase in prevalence of communicable diseases. India is expected to be an emerging and the fastest growing market. The live attenuated vaccines market shows steady growth in the Middle East & Africa.

The report for live attenuated vaccines market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. 

The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the live attenuated vaccines market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions